All In Biotech

Drug Trial Radar · NCT07843056

A Clinical Trial to Compare the Efficacy and Safety of WAS123 Versus Daily Aripiprazole in the Maintenance Treatment of Patients With Schizophrenia.

A Phase II, Proof-of-concept, National, Multicenter, Randomized, Double-blind Clinical Trial to Compare the Efficacy and Safety of WAS123 Versus Daily Aripiprazole in the Maintenance Treatment of Patients With Schizophrenia.

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 121 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

121

Actual

Start

May 10, 2022

Primary completion

Jan 20, 2026

Study completion Mar 23, 2026

Sponsor

Lead sponsor
EMSIndustry
Sponsor type
Industry
Collaborators
Worldwide Clinical Trials
First posted
Sep 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase II, proof-of-concept, national, multicenter, randomized, double-blind clinical trial to compare the efficacy and safety of WAS123 in the maintenance treatment of patients with schizophrenia, with a parallel design between 2 groups and controlled by an active comparator (Aripiprazole). A total of 121 participants were randomized and assigned to either 1 of 2 treatment groups in a 1:1 ratio.

Conditions

  • Schizophenia Disorder

Interventions

  • WAS123Drug

    oral dose

  • Aripiprazole (Fixed dose)Drug

    oral daily dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Score PANSSTime frame: From enrollment to the end of treatment at 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinica Viver

    São Paulo, São Paulo, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.